RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Late-breaking data presented at WCLC highlight significant and sustained improvements in overall survival, including more than doubling five-year survival rates compared to chemotherapy alone
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
Philips and Masimo will also collaborate on the development and co-promotion of next-generation monitoring solutions
The FDA is beginning rulemaking to close the “adequate provision” loophole
Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
Subscribe To Our Newsletter & Stay Updated